Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual Meeting Preliminary data from the ongoing Phase ...

As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...

JT Thorpe Group, backed by HIG Capital, has acquired ThorCan Construction & Refractories, a Burlington, Ontario-based provider of specialized refractory services. ThorCan, founded in 2003, provides ...

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

CERo Therapeutics (CERO) will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer conference being held ...

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

Dexmedetomidine by subcutaneous infusion can safely improve refractory pain and agitated delirium in hospice patients while ...

Sequencing treatment for patients with relapsed or refractory multiple myeloma depends on the patient’s disease and history, explained Lisa Hwa Christenson, DNP, APRN, CNP, associate professor of ...

Among these, the clinical study of their drug candidate LBL-034 will be highlighted as the first oral presentation on the opening day, showcasing its promising efficacy and safety in treating relapsed ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

The ASH abstract published today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the June 30 th, ...